Proteome Sciences Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Mariola Sohngen
Chief executive officer
UK£261.0k
Total compensation
| CEO salary percentage | 95.4% |
| CEO tenure | 4.3yrs |
| CEO ownership | n/a |
| Management average tenure | 7.4yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely
May 10
Here's Why We Think Proteome Sciences (LON:PRM) Is Well Worth Watching
Dec 02Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors
Aug 25Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors
Dec 22Do Proteome Sciences' (LON:PRM) Earnings Warrant Your Attention?
Sep 03Calculating The Fair Value Of Proteome Sciences plc (LON:PRM)
Jan 27Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?
May 31Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/E
Apr 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£4m |
| Mar 31 2024 | n/a | n/a | -UK£3m |
| Dec 31 2023 | UK£261k | UK£249k | -UK£2m |
| Sep 30 2023 | n/a | n/a | -UK£879k |
| Jun 30 2023 | n/a | n/a | UK£684k |
| Mar 31 2023 | n/a | n/a | UK£1m |
| Dec 31 2022 | UK£310k | UK£247k | UK£1m |
| Sep 30 2022 | n/a | n/a | UK£943k |
| Jun 30 2022 | n/a | n/a | UK£560k |
| Mar 31 2022 | n/a | n/a | UK£316k |
| Dec 31 2021 | UK£258k | UK£235k | UK£72k |
| Sep 30 2021 | n/a | n/a | UK£228k |
| Jun 30 2021 | n/a | n/a | UK£384k |
| Mar 31 2021 | n/a | n/a | UK£340k |
| Dec 31 2020 | UK£252k | UK£73k | UK£295k |
Compensation vs Market: Mariola's total compensation ($USD324.84K) is about average for companies of similar size in the UK market ($USD350.47K).
Compensation vs Earnings: Mariola's compensation has been consistent with company performance over the past year.
CEO
Mariola Sohngen (63 yo)
4.3yrs
Tenure
UK£261,000
Compensation
Dr. Mariola Sohngen serves as Chief Executive Officer and Executive Director at Proteome Sciences plc since September 15, 2020. Dr. Söhngen served as a Member of the Executive Board of Mologen AG since Nov...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.3yrs | UK£261.00k | no data | |
| CFO & Director | 2.3yrs | UK£212.00k | no data | |
| Chief Scientific Officer & Executive Director | 8.1yrs | UK£245.00k | 0.056% £ 7.3k | |
| Chief Commercial Officer & Executive Director | 7.8yrs | UK£207.00k | 0.21% £ 27.4k | |
| Company Secretary | 7.4yrs | no data | no data |
7.4yrs
Average Tenure
61.5yo
Average Age
Experienced Management: PRM's management team is seasoned and experienced (7.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.3yrs | UK£261.00k | no data | |
| CFO & Director | 2.3yrs | UK£212.00k | no data | |
| Chief Scientific Officer & Executive Director | 14.3yrs | UK£245.00k | 0.056% £ 7.3k | |
| Chief Commercial Officer & Executive Director | 6.8yrs | UK£207.00k | 0.21% £ 27.4k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Non Executive Chairman | 30.5yrs | UK£62.00k | 12.51% £ 1.6m | |
| Independent Non Executive Director | 10.5yrs | UK£35.00k | 1.15% £ 149.3k | |
| Chairman of Scientific Advisory Board | no data | UK£16.00k | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 7.4yrs | UK£33.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.4yrs
Average Tenure
66yo
Average Age
Experienced Board: PRM's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 09:11 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Proteome Sciences plc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Cavendish |
| Navid Malik | Cavendish Historical (Cenkos Securities) |
| Michael Thomas Cooper | Edison Investment Research |